FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012319527> ?p ?o ?g. }

• W2012319527 endingPage "301" @default.
• W2012319527 startingPage "294" @default.
• W2012319527 abstract "Cilengitide (EMD 121974) is a selective inhibitor of integrins αvβ3 and αvβ5. The αvβ3 promotes the proliferation of tumor-associated endothelial cells and potentially the survival of melanoma cells. We conducted a randomized phase II trial in patients with metastatic melanoma to evaluate the clinical efficacy of cilengitide. Patients with stage IV or unresectable stage III melanoma who were either chemonaive or who had previously received one systemic therapy were enrolled. Patients were randomly assigned to either 500 or 2000 mg of cilengitide administered intravenously twice weekly. The primary aim of this study was to determine the progression-free survival rate at 8 weeks. Tumor samples and blood samples were collected for pharmacodynamic and pharmacokinetic studies. Twenty-nine patients were enrolled, of whom 26 were treated (14 at 500 mg and 12 at 2000 mg). Among those treated, only three were progression free at 8 weeks: two in the 500 mg arm and one in the 2000 mg arm. One patient in the 2000 mg arm showed a prolonged partial response after an initial 28% enlargement of her target lesions. The treatment was well tolerated without clinically significant adverse events. The sole responder and one of two patients with stable disease had no αvβ3 expression at baseline. Overall, αvβ3 expression was decreased by day 8 of the treatment (P=0.05). Cilengitide was well tolerated by patients in both the treatment arms but had minimal clinical efficacy as a single-agent therapy for metastatic melanoma, and the efficacy was not related to baseline αvβ3 expression." @default.
• W2012319527 created "2016-06-24" @default.
• W2012319527 creator A5003799076 @default.
• W2012319527 creator A5010742248 @default.
• W2012319527 creator A5011465880 @default.
• W2012319527 creator A5015498468 @default.
• W2012319527 creator A5026562050 @default.
• W2012319527 creator A5032988793 @default.
• W2012319527 creator A5033798832 @default.
• W2012319527 creator A5034715033 @default.
• W2012319527 creator A5038143218 @default.
• W2012319527 creator A5041906408 @default.
• W2012319527 creator A5053460346 @default.
• W2012319527 creator A5060563693 @default.
• W2012319527 creator A5069230926 @default.
• W2012319527 creator A5069613777 @default.
• W2012319527 creator A5078841756 @default.
• W2012319527 creator A5087156478 @default.
• W2012319527 date "2012-08-01" @default.
• W2012319527 modified "2023-09-24" @default.
• W2012319527 title "A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma" @default.
• W2012319527 cites W2000366267 @default.
• W2012319527 cites W2013381560 @default.
• W2012319527 cites W2013417615 @default.
• W2012319527 cites W2014825000 @default.
• W2012319527 cites W2019003423 @default.
• W2012319527 cites W2026629688 @default.
• W2012319527 cites W2029409133 @default.
• W2012319527 cites W2034842897 @default.
• W2012319527 cites W2050384949 @default.
• W2012319527 cites W2065097700 @default.
• W2012319527 cites W2068124694 @default.
• W2012319527 cites W2072103796 @default.
• W2012319527 cites W2077090481 @default.
• W2012319527 cites W2100363932 @default.
• W2012319527 cites W2100577875 @default.
• W2012319527 cites W2109088595 @default.
• W2012319527 cites W2109513968 @default.
• W2012319527 cites W2115516828 @default.
• W2012319527 cites W2120536808 @default.
• W2012319527 cites W2132607958 @default.
• W2012319527 cites W2139248078 @default.
• W2012319527 cites W2150456585 @default.
• W2012319527 cites W2151261375 @default.
• W2012319527 doi "https://doi.org/10.1097/cmr.0b013e32835312e4" @default.
• W2012319527 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3880198" @default.
• W2012319527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22668797" @default.
• W2012319527 hasPublicationYear "2012" @default.
• W2012319527 type Work @default.
• W2012319527 sameAs 2012319527 @default.
• W2012319527 citedByCount "52" @default.
• W2012319527 countsByYear W20123195272013 @default.
• W2012319527 countsByYear W20123195272014 @default.
• W2012319527 countsByYear W20123195272015 @default.
• W2012319527 countsByYear W20123195272016 @default.
• W2012319527 countsByYear W20123195272017 @default.
• W2012319527 countsByYear W20123195272018 @default.
• W2012319527 countsByYear W20123195272019 @default.
• W2012319527 countsByYear W20123195272020 @default.
• W2012319527 countsByYear W20123195272021 @default.
• W2012319527 countsByYear W20123195272022 @default.
• W2012319527 countsByYear W20123195272023 @default.
• W2012319527 crossrefType "journal-article" @default.
• W2012319527 hasAuthorship W2012319527A5003799076 @default.
• W2012319527 hasAuthorship W2012319527A5010742248 @default.
• W2012319527 hasAuthorship W2012319527A5011465880 @default.
• W2012319527 hasAuthorship W2012319527A5015498468 @default.
• W2012319527 hasAuthorship W2012319527A5026562050 @default.
• W2012319527 hasAuthorship W2012319527A5032988793 @default.
• W2012319527 hasAuthorship W2012319527A5033798832 @default.
• W2012319527 hasAuthorship W2012319527A5034715033 @default.
• W2012319527 hasAuthorship W2012319527A5038143218 @default.
• W2012319527 hasAuthorship W2012319527A5041906408 @default.
• W2012319527 hasAuthorship W2012319527A5053460346 @default.
• W2012319527 hasAuthorship W2012319527A5060563693 @default.
• W2012319527 hasAuthorship W2012319527A5069230926 @default.
• W2012319527 hasAuthorship W2012319527A5069613777 @default.
• W2012319527 hasAuthorship W2012319527A5078841756 @default.
• W2012319527 hasAuthorship W2012319527A5087156478 @default.
• W2012319527 hasBestOaLocation W20123195272 @default.
• W2012319527 hasConcept C111113717 @default.
• W2012319527 hasConcept C112705442 @default.
• W2012319527 hasConcept C121608353 @default.
• W2012319527 hasConcept C126322002 @default.
• W2012319527 hasConcept C143998085 @default.
• W2012319527 hasConcept C168563851 @default.
• W2012319527 hasConcept C197934379 @default.
• W2012319527 hasConcept C2776694085 @default.
• W2012319527 hasConcept C2777658100 @default.
• W2012319527 hasConcept C2778822529 @default.
• W2012319527 hasConcept C2994587330 @default.
• W2012319527 hasConcept C31760486 @default.
• W2012319527 hasConcept C502942594 @default.
• W2012319527 hasConcept C535046627 @default.
• W2012319527 hasConcept C71924100 @default.
• W2012319527 hasConcept C90924648 @default.
• W2012319527 hasConceptScore W2012319527C111113717 @default.
• W2012319527 hasConceptScore W2012319527C112705442 @default.

• next